Here's Why ResMed (RMD) is a Strong Growth Stock

Zacks highlights ResMed (RMD), a global leader in sleep-disordered breathing devices, as a strong growth prospect, despite its Zacks Rank #3 (Hold), due to its 'A' Growth Style Score and 'A' VGM Score. The company is forecasted for 13.7% year-over-year earnings growth for the current fiscal year, supported by recent upward revisions from seven analysts, pushing the FY2026 consensus estimate to $10.86 per share. This analysis exemplifies how Zacks Style Scores, which rate stocks on value, growth, and momentum, complement the Zacks Rank to identify high-probability investment opportunities, making RMD a potential addition to investor shortlists.

Analysis

ResMed, Inc. (RMD) presents a positive outlook for growth-focused investors, despite its neutral Zacks #3 (Hold) rating. The company's fundamental strength is underscored by its top-tier 'A' ratings for both its Growth Style Score and its overall VGM Score. This positive assessment is quantitatively supported by a forecast for 13.7% year-over-year earnings growth in the current fiscal year. Analyst sentiment is clearly improving, evidenced by seven upward earnings estimate revisions for fiscal 2026 within the last 60 days. These revisions have collectively lifted the Zacks Consensus Estimate for FY2026 by $0.43 to $10.86 per share. Furthermore, RMD has a consistent history of outperformance, boasting an average positive earnings surprise of 4.5%. This combination of strong forward-looking growth indicators and positive estimate revisions suggests underlying fundamental momentum that may not yet be fully reflected in its neutral rank.

Key Decisions for Investors

• Given the 'A' Growth Score and a forecasted 13.7% earnings growth, investors with a growth-oriented strategy should consider placing ResMed on their shortlist for potential investment.
• Investors should monitor for any potential upgrade in RMD's Zacks Rank from its current #3 (Hold), as such a change would serve as a strong confirmation of the positive underlying analyst sentiment and could act as a catalyst for the stock.
• It is prudent to weigh the strong forward-looking growth metrics and positive earnings revisions against the current neutral 'Hold' rating, which suggests that near-term price action may remain range-bound until the positive catalysts become more widely recognized.